Verve Therapeutics’ VERVE-102 Shows Promising Bad Cholesterol Results
Verve Therapeutics announced that its Phase Ib trial showed significant reductions in bad cholesterol, setting up a showdown with Novartis’ Leqvio and other PCSK9 inhibitors. The therapy, VERVE-102, targets the PCSK9 gene specifically in the liver to reduce low-density lipoprotein cholesterol (LDL-C) levels. The results demonstrated dose-dependent reductions in LDL-C, with the lowest dose yielding … Read more